Novel antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) show even higher efficacy with acceptable side-effect profiles in the treatment of metastatic HER2-positive BC than what was previously achieved with T-DM1. Here, ERBB2 is linked to breast cancer.